Brittany Meiling – Page 14 – Endpoints News

about the author

Brittany Meiling

editors@endpointsnews.com

Brittany Meiling on LinkedIn

author articles

Faheem Hasnain and his ex-Receptos team launch a new biotech with $100M and a twist on the old biotech model

8 years ago

SVB's crystal ball points to big money biotech IPOs, downshift in the torrid pace of venture investing

8 years ago

Novartis backs eye drop maker in $20M round, meds to fill gap left by Eylea/Lucentis

8 years ago

All in: Boehringer Ingelheim more than doubles its venture fund to €250M

8 years ago

Biogen vet Jean-Paul Kress takes the reins at NYC's Syntimmune

8 years ago

A better approach to growth factors? Scholar Rock raises $47M on SMA promise

8 years ago

Chinese dealmaking: SARI nabs Italy’s NMS Group for $362M; Inovio retools deal with ApolloBio

8 years ago

Ex-Pfizer CEO's startup Centrexion gets $67M for PhIII painkiller

8 years ago

Denied: FDA rejects Agile's contraception patch for second time

8 years ago

Following cancer combo deal with Bristol-Myers, Taris gets $25M Series B

8 years ago

Kymriah, Yescarta found 'cost-effective' in treating cancer, despite high price

8 years ago

Backed by Henri Termeer estate, Aura raises $30M for work to prevent blindness in eye cancer patients

8 years ago

In gene therapy's second big win this week, Orchard nabs $110M Series B

8 years ago

Flagship adds $618M in new funds to fuel startup mission

8 years ago

After axing a top drug, Millendo bags a PhII replacement with biotech buyout

8 years ago

Array joins Pfizer on anti-cancer combos, the latest in a string of binimetinib combinations

8 years ago

Apotex founder and wife's death now suspected homicide; Spectrum CEO Rajesh Shrotriya fired

8 years ago

Severe job cuts at Teva incite massive worker strikes, shutting Israel down

8 years ago

Four months after patient death, FDA's hold lifted on Alnylam's fitusiran

8 years ago

The 50 most active biotech VC funds in 2017

8 years ago

Jnana launches with $50M to spotlight an unexplored protein territory

8 years ago

Bristol-Myers teams up with Opdivo maker Ono Pharmaceutical on new I/O programs

8 years ago

Its underlying biology 'too complicated' for further investment, Atlas-seeded Raze signs off

8 years ago

Atlas and OrbiMed back Boston's Kyn in $49M round to pursue immunometabolism therapies

8 years ago

First page Previous page 11 12 131415 16 17 Next page Last page